Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: RickV who wrote (110)	5/22/1998 8:46:00 AM
From: BARRY ALLEN	Read Replies (2) \| Respond to of 4891

Hey guys.....didn't anyone notice??? REUTERS picked up the news yesterday!! That is the first time ADVR had coverage from them. REUTERS is worldwide!! We hung in this long so keep the faith because things seem to be brewing here for the first time in a long time. I am leaving on vacation today and will be back June 1. I will try to get access online while I'm away. I'll will be in the D.C. area and NJ again. No, I'm not going to the Lab but maybe I'll visit with CUBBY! ************************************************************** Thursday May 21, 7:52 pm Eastern Time Advanced Viral drug gets immune response YONKERS, N.Y., May 21 (Reuters) - Advanced Viral Research Corp said Thursday Phase 3 clinical trials of Reticulose on adults infected with HIV showed early, sustained improvements in CD4 and CD8 cell counts, significant decreases in viral loads, significant weight gain, fewer opportunistic infections and lowered mortality, compared to patients receiving placebo. The abstract describing these findings is one of only 3 percent of submitted abstracts to be highlighted by the American Society for Microbiology at its 98th Annual Meeting in Atlanta, Advanced Viral noted. Reticulose is a non-toxic peptide-nucleic acid that stimulates the cytocidal arm of the immune system. ''Available treatments for AIDS have focused on eradicating HIV from the body. Although there have been significant advances in anti-retroviral treatment, attempts to stimulate recovery of the immune system -- the target of HIV infection -- have been less successful,'' said Shalom Hirschman, chief executive officer of Advanced Viral. ''The ability of the body to stimulate immune system repair through internal cellular production of cytokines may be an important missing piece of the AIDS treatment puzzle, and may thus offer a new approach to treating this disease.'' The company said these clinical results build on the promise of earlier laboratory studies, in which Reticulose appeared to mediate repair of the immune system. By helping the immune system repair itself, Reticulose may offer a new approach to treating HIV infection, it added. Reticulose, which was initially developed in the 1930's to treat influenza, stimulates cytokine production, the company said. Internal cellular production of cytokines may be more effective than externally administered cytokines in treating viruses such as HIV. biz.yahoo.com